Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
Presenter
Richard S. Finn, MD
Department of Medicine, Hematology/Oncology, David Geffen School of Medicine at University of California Los Angeles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT03412773
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 495)
DOI
10.1200/JCO.2023.41.4_suppl.495
Abstract #
495
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Breakthrough
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
Speaker: Masatoshi Kudo, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Speaker: Peter Robert Galle, MD, PhD
Videos & Slides
2023 ASCO Annual Meeting
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
Speaker: Ari David Baron, MD
Videos & Slides
2020 Gastrointestinal Cancers Symposium
Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
Speaker: Peter R. Galle, MD, PhD